Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSL's Total Liabilities for the quarter that ended in Jun. 2026 was MXN302,548 Mil.
CSL's quarterly Total Liabilities
declined
from Jun. 2025 (MXN338,869.11 Mil) to Dec. 2025 (MXN314,055.42 Mil) and
declined
from Dec. 2025 (MXN314,055.42 Mil) to Jun. 2026 (MXN302,548.21 Mil).
CSL's annual Total Liabilities
declined
from Jun. 2024 (MXN341,138.64 Mil) to Jun. 2025 (MXN338,869.11 Mil) and
declined
from Jun. 2025 (MXN338,869.11 Mil) to Jun. 2026 (MXN302,548.21 Mil).
The historical data trend for CSL's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
CSL's Total Liabilities for the fiscal year that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of MXN302,548 Mil mean?
CSL (MEX:CSL N) has a Total Liabilities of MXN302,548 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CSL and its competitors.
Is CSL's Total Liabilities too high?
CSL's current Total Liabilities is MXN302,548 Mil. Overall, CSL has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does CSL's Total Liabilities compare to VRTX and REGN?
CSL's Total Liabilities of MXN302,548 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CSL and its competitors. CSL's current Total Liabilities is MXN302,548 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
CSL (MEX:CSL N) has a current Total Liabilities of MXN302,548 Mil. The stock's GF Value™ is MXN3,715.40, compared to a current price of MXN2,081.30 — trading 44% below its estimated fair value. The current Total Liabilities is MXN302,548 Mil. CSL's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For CSL (MEX:CSL N), the current Total Liabilities is MXN302,548 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (MEX:CSL N) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of MXN2,081.30 is trading 44% below its estimated GF Value™ of MXN3,715.40.
Key valuation signals for MEX:CSL N:
Total Liabilities: MXN302,548 Mil
GF Value™: MXN3,715.40 vs. price of MXN2,081.30 (44% below fair value)
No single metric tells the full story. See the MEX:CSL N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
75GF Score
Get the complete analysis for MEX:CSL N
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:CSL N has been successfully added to your 
